^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR1316, SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4d
    Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=124, Recruiting, Air Force Military Medical University, China
    New P2 trial • Real-world evidence
    |
    cisplatin • gemcitabine • AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    5d
    A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2/3, N=165, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    5d
    A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=156, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • paclitaxel • pemetrexed • Ameile (aumolertinib) • AiRuiLi (adebrelimab) • ruzaltatug rezetecan (SHR-A2009) • tizetatug rezetecan (SHR-A1921)
    5d
    Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • AiRuiLi (adebrelimab)
    5d
    Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in Small Cell Lung Cancer: An In Vitro Study. (PubMed, Curr Med Chem)
    In summary, the combination of Apa and Ade represented a promising innovative therapeutic strategy for SCLC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • KDR (Kinase insert domain receptor) • IFNG (Interferon, gamma) • STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    6d
    SHR-8068-301: A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=590, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Tyvyt (sintilimab) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)
    9d
    Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=204, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P3 trial
    |
    AiRuiLi (adebrelimab)
    10d
    A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    carboplatin • AiRuiLi (adebrelimab)
    11d
    NEOVADE: Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Guangdong Provincial People's Hospital | Trial completion date: Sep 2027 --> Apr 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    carboplatin • albumin-bound paclitaxel • Ameile (aumolertinib) • AiRuiLi (adebrelimab)
    12d
    RAIN-HNSCC: Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Chen Chunyan
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiLi (adebrelimab)
    17d
    A Phase II Prospective Clinical Study of Adebrelimab combined with Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease (ChiCTR2600121738)
    P=N/A, N=60, inling Hospital, Affiliated Hospital of Medical School, Nanjing University; Jinling Hospital, Affiliated Hospital of Medical School, Nanjing Universit
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK fusion • ROS1 fusion
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • AiRuiLi (adebrelimab)
    17d
    Adebrelimab combined with apatinib and platinum-based chemotherapy for neoadjuvant treatment of potentially resectable thymic carcinoma: A single-center, single-arm, phase II clinical study (ChiCTR2600121533)
    P2, N=20, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P2 trial
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)